

11-nor-Delta-9-Tetrahydrocannabinol-9-Carbo xylic Acid (Carboxy-THC) Confirmation,

Meconium

## Overview

#### **Useful For**

Detecting in utero drug exposure to marijuana (tetrahydrocannabinol) up to 5 months before birth

## **Special Instructions**

• Clinical Toxicology CPT Code Client Guidance

### **Method Name**

Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

#### **NY State Available**

Yes

## **Specimen**

## **Specimen Type**

Meconium

## **Ordering Guidance**

For chain-of-custody testing, order THCMX / 11-nor-Delta-9-Tetrahydrocannabinol-9-Carboxylic Acid (Carboxy-THC) Confirmation, Chain of Custody, Meconium.

## **Specimen Required**

Supplies: Stool container, Small (Random), 4 oz (T288)

Container/Tube: Stool container

Specimen Volume: 1 g (approximately 1 teaspoon)

**Collection Instructions:** Collect entire random meconium specimen.

## **Forms**

If not ordering electronically, complete, print, and send a <u>Therapeutics Test Request</u> (T831) with the specimen.

### Specimen Minimum Volume

0.3 g (approximately 1/4 teaspoon)

## Reject Due To

Grossly bloody	Reject; Pink OK
Stool;	Reject



11-nor-Delta-9-Tetrahydrocannabinol-9-Carbo xylic Acid (Carboxy-THC) Confirmation,

Meconium

Diapers				

## **Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Meconium	Frozen (preferred)	28 days	
	Ambient	14 days	
	Refrigerated	21 days	

## Clinical & Interpretive

#### **Clinical Information**

Marijuana and other psychoactive products obtained from the plant *Cannabis sativa* are the most widely used illicit drugs in the world.(1) Marijuana has unique behavioral effects that include feelings of euphoria and relaxation, altered time perception, impaired learning and memory, lack of concentration, and mood changes (eg, panic reactions and paranoia).

Cannabis sativa produces numerous compounds collectively known as cannabinoids, including delta-9-tetrahydrocannabinol (THC), which is the most prevalent and produces most of the characteristic pharmacological effects of smoked marijuana.(2) THC undergoes rapid hydroxylation by the cytochrome enzyme system to form the active metabolite 11-hydroxy-THC. Subsequent oxidation of 11-hydroxy-THC produces the inactive metabolite 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH; carboxy-THC). THC-COOH and its glucuronide conjugate have been identified as the major end-products of metabolism. THC is highly lipid soluble, resulting in its concentration and prolonged retention in fat tissue.(3)

Cannabinoids cross the placenta, but a dose-response relationship or correlation has not been established between the amount of marijuana use during pregnancy and the levels of cannabinoids found in meconium, the first fecal matter passed by the neonate. (4,5) The disposition of drug in meconium is not well understood. The proposed mechanism is that the fetus excretes drug into bile and amniotic fluid. Drug accumulates in meconium either by direct deposition from bile or through swallowing amniotic fluid. (5) The first evidence of meconium in the fetal intestine appears at approximately the 10th to 12th week of gestation, and it slowly moves into the colon by the 16th week of gestation. (6) Therefore, the presence of drugs in meconium has been proposed to be indicative of in utero drug exposure during the final 4 to 5 months of pregnancy, a longer historical measure than is possible by urinalysis. (5)

#### **Reference Values**

Negative

Positive results are reported with a quantitative liquid chromatography tandem mass spectrometry result.

Cutoff concentration: 5 ng/g



11-nor-Delta-9-Tetrahydrocannabinol-9-Carbo xylic Acid (Carboxy-THC) Confirmation,

Meconium

#### Interpretation

The presence of 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid at 5 ng/g or greater is indicative of in utero drug exposure up to 5 months before birth.

#### **Cautions**

No significant cautionary statements.

#### **Clinical Reference**

- 1. Huestis MA. Marijuana. In: Levine B, ed. Principles of Forensic Toxicology. 2nd ed. AACC Press; 2003:229-264
- 2. O'Brein CP. Drug addiction and drug abuse. In: Burton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill; 2006
- 3. Baselt RC. Disposition of Toxic Drugs and Chemical in Man. 12th ed. Biomedical Publications; 2020
- 4. Ostrea EM Jr, Knapp DK, Tannenbaum L, et al. Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis. J Pediatr. 2001;138(3):344-348
- 5. Ostrea EM Jr, Brady MJ, Parks PM, Asensio DC, Naluz A. Drug screening of meconium in infants of drug-dependent mothers: an alternative to urine testing. J Pediatr. 1989;115(3):474-477
- 6. Ahanya SN, Lakshmanan J, Morgan BL, Ross MG. Meconium passage in utero: mechanisms, consequences, and management. Obstet Gynecol Surv. 2005;60(1):45-74
- 7. Langman LJ, Bechtel LK, Holstege CP. Clinical toxicology. In: Rifai N, Chiu RWK, Young I, Burnham C-AD, Wittwer CT, eds. Tietz Textbook of Laboratory Medicine. 7th ed. Elsevier; 2023:chap 43

## **Performance**

## **Method Description**

Meconium is mixed with internal standard and extracted with methanol. The methanolic extract is further processed by solid phase extraction. The extract is analyzed by liquid chromatography tandem mass spectroscopy. (Unpublished Mayo method)

## **PDF Report**

No

#### Day(s) Performed

Monday through Sunday

## **Report Available**

2 to 3 days

## **Specimen Retention Time**

2 weeks

## **Performing Laboratory Location**

Mayo Clinic Laboratories - Rochester Superior Drive



11-nor-Delta-9-Tetrahydrocannabinol-9-Carbo xylic Acid (Carboxy-THC) Confirmation,

Meconium

## **Fees & Codes**

#### **Fees**

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact <u>Customer Service</u>.

#### **Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

## **CPT Code Information**

G0480

80349 (if appropriate for select payers)

Clinical Toxicology CPT Code Client Guidance

#### **LOINC®** Information

Test ID	Test Order Name	Order LOINC® Value
THCM	Carboxy-THC Confirmation, M	69007-3

Result ID	Test Result Name	Result LOINC® Value
31863	Carboxy-THC	69007-3
31876	Interpretation	69050-3
31877	Chain of Custody	77202-0